Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Michael J. Austin et al.|Blood|2023Cited by 65
Pretransplant MRD detection of fusion transcripts is strongly prognostic in <i>KMT2A-</i>rearranged acute myeloid leukemiaSun Loo, Andrew H. Wei, Nicola Potter et al.|Blood|2024Cited by 13
Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III studyGuillermo Garcia‐Manero, Lionel Adès, Maciej Kaźmierczak et al.|Leukemia Research|2024Cited by 12